Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC disclosures from a clinical-stage biotech like Arcellx can stretch hundreds of pages packed with trial protocols, cash-burn tables, and FDA correspondence. Locating the exact cash-runway figure or deciphering an Arcellx annual report 10-K simplified often demands specialist knowledge and hours of scrolling.
Stock Titan removes that friction. Our AI reads every document the moment it lands on EDGAR, turning raw text into plain-language highlights. Open an Arcellx quarterly earnings report 10-Q filing to see R&D spend, enrollment numbers, and liquidity ratios summarized in seconds. Each Arcellx 8-K material events explained module pinpoints trial pauses, new partnerships, or financing rounds, while Arcellx insider trading Form 4 transactions appear in real time so you can track sentiment. Need deeper context? Trend graphs group every Arcellx executive stock transactions Form 4 and flag unusual activity.
The page goes beyond surface data. Our earnings report filing analysis compares sequential R&D trends, and the Arcellx proxy statement executive compensation section links leadership pay to pipeline milestones. Toggle from AI commentary to the source file with one click—perfect for understanding Arcellx SEC documents with AI while keeping primary evidence close. Whether you’re scanning Arcellx Form 4 insider transactions real-time before a trade or need Arcellx SEC filings explained simply for diligence, this hub delivers comprehensive coverage and insight you can act on.
Heery Christopher, Chief Medical Officer of Arcellx, Inc. (ACLX), reported sales of company common stock under a Rule 10b5-1 trading plan. On 09/18/2025 he sold 3,343 shares at a weighted average price of $80.0085, leaving him with 34,427 shares beneficially owned after that transaction. On 09/19/2025 he sold an additional 300 shares at $80.00, leaving 34,127 shares beneficially owned. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
The filing notes the sales were effected pursuant to a 10b5-1 plan entered March 23, 2025, and that the post-transaction totals include 284 shares acquired under the issuer's 2022 Employee Stock Purchase Plan on May 14, 2025. No derivative transactions or other changes were reported.
Arcellx, Inc. (ACLX) filed a Form 144 notifying the proposed sale of 37,486 common shares through Morgan Stanley Smith Barney on 09/18/2025 with an aggregate market value of $2,864,680.12. The filing lists total shares outstanding as 55,458,912, meaning the proposed sale equals approximately 0.0676% of outstanding shares. The securities being offered were acquired through three routes: restricted stock units granted on 01/02/2025 (28,208 shares), participation in an employee stock purchase plan on 05/12/2023 (1,483 shares), and previously exercised stock options on 09/03/2024 (7,795 shares). No securities were reported sold in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
T. Rowe Price Investment Management, Inc. reports holding 6,275,907 shares of Arcellx Inc. common stock, representing 11.3% of the class. The filing shows 6,135,986 shares with sole voting power and 6,275,204 shares with sole dispositive power, with no shared voting or dispositive power reported. The filer states these shares are held in the ordinary course of business and not for the purpose of influencing control. The Schedule 13G classification and disclosed holdings indicate a material passive stake above the 5% reporting threshold.
Arcellx insider transaction: Rami Elghandour, President, CEO and Chairman, reported a disposition of 546,938 shares of Arcellx common stock on 08/28/2025 at a reported price of $70.25 per share. The filing states these shares were forfeited to satisfy the reporting person’s tax withholding obligations in connection with the settlement of performance-based restricted stock units that vested on February 27, 2025. After the reported disposition, the reporting person beneficially owns 617,919 shares. The Form 4 was signed by an attorney-in-fact on 08/29/2025.
Amendment No. 4 to Schedule 13D reports that New Enterprise Associates 15, L.P. ("NEA 15") now holds 3,045,262 shares of Arcellx, Inc. common stock, which the filing states represents 5.49% of the 55,458,912 shares outstanding used for the calculation. The amendment documents pro rata distributions on August 12, 2025: NEA 15 distributed 700,000 shares to its partners and NEA Partners 15 distributed 168,217 shares to its limited partners, resulting in NEA 15 holding the stated 3,045,262 shares.
The filing clarifies that the Reporting Persons (NEA entities and four named managers) acquired and hold the shares for investment purposes and currently have no present plans to effectuate transactions or corporate changes such as mergers, board changes, material asset sales or changes to capitalization. The cover sheets show shared voting and dispositive power over the NEA 15 Shares and reflect that Scott D. Sandell may be deemed to beneficially own additional small blocks held in trusts, giving him an aggregate 3,055,360 shares (5.51%).
Arcellx, Inc. (ACLX) Form 4 filed for reporting person Ali Behbahani shows pro rata distributions of common stock from NEA Partners 15, L.P. on August 12, 2025. The reporting person received 1,586 shares directly, recorded as an acquisition at $0.00. The Ali Behbahani Revocable Trust dated June 26, 2015 received 2,621 shares in the same distribution; the trust holds those shares directly while Mr. Behbahani disclaims beneficial ownership for any portion where he lacks a pecuniary interest. Post-transaction holdings are reported as 1,925 shares direct and 2,706 shares indirect.
Perceptive Advisors and affiliated parties reported beneficial ownership of 2,478,000 shares of Arcellx, Inc. (ACLX), representing 4.5% of the outstanding common stock based on 55,458,912 shares outstanding as of August 1, 2025. The filing shows the Master Fund directly holds the 2,478,000 shares, with Perceptive Advisors serving as investment manager and Joseph Edelman identified as managing member. All three reporting persons report shared voting and dispositive power over those shares and report no sole voting or dispositive power. The Schedule 13G/A is filed under the passive investor framework and contains standard certifications and signatures by Joseph Edelman.
FAQ
What is the current stock price of ARCELLX (ACLX)?
What is the market cap of ARCELLX (ACLX)?
